The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants

Key facts

Sponsor

University of Virginia

Principal Investigator

D Sc Lim, MD, M.D

University of Virginia

Intervention

Withhold standard INDO dose if BNP < 100 pg/ml(procedure)

Enrollment

60 enrolled

Eligibility

All sexes

Timeline

2004 – 2007

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Arterial duct anomaly

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT06950164
  Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• RECRUITINGNCT06658496
  PDA for Kidneys Study
  University of Wisconsin, Madison
• RECRUITINGNCT06646250
  NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot
  St. Olavs Hospital
• RECRUITINGPHASE2NCT07143201
  Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
  Hamilton Health Sciences Corporation
• RECRUITINGNCT05264753
  Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
  Occlutech International AB
• ACTIVE NOT RECRUITINGNCT04371081
  Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance
  Abbott Medical Devices
• ACTIVE NOT RECRUITINGNCT03782610
  Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
  Nationwide Children's Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT03456336
  Management of the PDA Trial
  NICHD Neonatal Research Network

See all trials for Arterial duct anomaly →